WO2001008669A3 - Agents therapeutiques - Google Patents

Agents therapeutiques Download PDF

Info

Publication number
WO2001008669A3
WO2001008669A3 PCT/GB2000/002950 GB0002950W WO0108669A3 WO 2001008669 A3 WO2001008669 A3 WO 2001008669A3 GB 0002950 W GB0002950 W GB 0002950W WO 0108669 A3 WO0108669 A3 WO 0108669A3
Authority
WO
WIPO (PCT)
Prior art keywords
lymphoedema
therapeutic agents
treatment
flk
kdr
Prior art date
Application number
PCT/GB2000/002950
Other languages
English (en)
Other versions
WO2001008669A2 (fr
Inventor
David Bates
Original Assignee
Univ Bristol
David Bates
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Bristol, David Bates filed Critical Univ Bristol
Priority to AU63023/00A priority Critical patent/AU6302300A/en
Publication of WO2001008669A2 publication Critical patent/WO2001008669A2/fr
Publication of WO2001008669A3 publication Critical patent/WO2001008669A3/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/235—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids having an aromatic ring attached to a carboxyl group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/502—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with carbocyclic ring systems, e.g. cinnoline, phthalazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/71—Assays involving receptors, cell surface antigens or cell surface determinants for growth factors; for growth regulators

Abstract

La présente invention concerne l'utilisation d'un agent qui inhibe ou empêche sélectivement le signal transduit par flk-1/KDR lorsqu'il est activé par un ligand ou qui interfère sélectivement avec ce dernier, dans la fabrication d'un médicament destiné à traiter le lymphoedème et dans un procédé permettant de réduire la vitesse de filtration du sang dans des tissus. On décrit également un procédé qui permet d'identifier des composés utiles dans le traitement du lymphoedème et des composés identifiés de la sorte.
PCT/GB2000/002950 1999-07-30 2000-07-31 Agents therapeutiques WO2001008669A2 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU63023/00A AU6302300A (en) 1999-07-30 2000-07-31 Therapeutic agents

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9918057.2A GB9918057D0 (en) 1999-07-30 1999-07-30 Therapeutic agents
GB9918057.2 1999-07-30

Publications (2)

Publication Number Publication Date
WO2001008669A2 WO2001008669A2 (fr) 2001-02-08
WO2001008669A3 true WO2001008669A3 (fr) 2002-07-11

Family

ID=10858334

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/GB2000/002950 WO2001008669A2 (fr) 1999-07-30 2000-07-31 Agents therapeutiques

Country Status (3)

Country Link
AU (1) AU6302300A (fr)
GB (1) GB9918057D0 (fr)
WO (1) WO2001008669A2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101880277A (zh) 2003-04-24 2010-11-10 因塞特公司 作为金属蛋白酶抑制剂的氮杂螺烷衍生物

Citations (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014748A1 (fr) * 1991-02-22 1992-09-03 American Cyanamid Company Identification d'un nouveau gene humain recepteur de tyrosine kinase
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
WO1995021613A1 (fr) * 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
WO1996040675A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes thienyliques pour l'inhibition des troubles dus a la proliferation cellulaire
WO1996040629A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes de type tyrphostine utilises pour le traitement de troubles de la proliferation cellulaire ou de troubles de la differenciation cellulaire
WO1996040648A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines et compositions pharmaceutiques
WO1997009427A1 (fr) * 1995-09-08 1997-03-13 Genentech, Inc. Proteine apparentee au vegf
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
WO1997034920A1 (fr) * 1996-03-21 1997-09-25 Sugen, Inc. Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
US5766860A (en) * 1992-11-23 1998-06-16 American Cyanamid Company Screening method using a recombinant kinase insert domain containing receptor and gene encoding same
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
WO1998039035A1 (fr) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Procede et compositions permettant de soigner les defauts tissulaires et d'induire l'hypervascularite dans des tissus mammiferes
WO1998055638A1 (fr) * 1997-06-03 1998-12-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sequences regulatrices capables de commander l'expression d'une sequence d'adn heterologue dans des cellules endotheliales in vivo et leurs utilisations
WO1998058053A1 (fr) * 1997-06-18 1998-12-23 Merck & Co., Inc. Tyrosine kinase receptrice, kdr
WO1999010537A1 (fr) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Suppresseur de tumeur appele ts10q23.3
US5891650A (en) * 1993-11-23 1999-04-06 Genentech Incorporated Kinase receptor activation assay
WO1999017769A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno(1,2-c)-, de naphto(1,2-c)-, et de benzo(6,7)cyclohepta(1,2-c)pyrazole
WO1999021859A1 (fr) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole, derives et applications
WO1999024440A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO2000058511A1 (fr) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)

Patent Citations (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992014748A1 (fr) * 1991-02-22 1992-09-03 American Cyanamid Company Identification d'un nouveau gene humain recepteur de tyrosine kinase
US5861301A (en) * 1992-02-20 1999-01-19 American Cayanamid Company Recombinant kinase insert domain containing receptor and gene encoding same
US5763441A (en) * 1992-11-13 1998-06-09 Sugen, Inc. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
WO1994011499A1 (fr) * 1992-11-13 1994-05-26 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Flk-1 UTILISE COMME RECEPTEUR POUR FACTEUR DE CROISSANCE ENDOTHELIAL VASCULAIRE
US5849742A (en) * 1992-11-13 1998-12-15 Sugen Inc. Compounds for the treament of disorders related to vasculogenesis and/or angiogenesis
US5792771A (en) * 1992-11-13 1998-08-11 Sugen, Inc. Quinazoline compounds and compositions thereof for the treatment of disease
US5712395A (en) * 1992-11-13 1998-01-27 Yissum Research Development Corp. Compounds for the treatment of disorders related to vasculogenesis and/or angiogenesis
US5766860A (en) * 1992-11-23 1998-06-16 American Cyanamid Company Screening method using a recombinant kinase insert domain containing receptor and gene encoding same
US5891650A (en) * 1993-11-23 1999-04-06 Genentech Incorporated Kinase receptor activation assay
US5766863A (en) * 1993-11-23 1998-06-16 Genentech, Inc. Kinase receptor activation assay
WO1995021613A1 (fr) * 1994-02-09 1995-08-17 Sugen, Inc. Composes destines au traitement de troubles associes a la vasculogenese et/ou a l'angiogenese
US5773459A (en) * 1995-06-07 1998-06-30 Sugen, Inc. Urea- and thiourea-type compounds
WO1996040675A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes thienyliques pour l'inhibition des troubles dus a la proliferation cellulaire
US5710173A (en) * 1995-06-07 1998-01-20 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
US5650415A (en) * 1995-06-07 1997-07-22 Sugen, Inc. Quinoline compounds
US5891917A (en) * 1995-06-07 1999-04-06 Sugen, Inc. Certain acrylonitrile-sulfonamide derivatives
US5886195A (en) * 1995-06-07 1999-03-23 Sugen, Inc. Thienyl compounds for inhibition of cell proliferative disorders
WO1996040629A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Composes de type tyrphostine utilises pour le traitement de troubles de la proliferation cellulaire ou de troubles de la differenciation cellulaire
WO1996040648A1 (fr) * 1995-06-07 1996-12-19 Sugen, Inc. Quinazolines et compositions pharmaceutiques
WO1997009427A1 (fr) * 1995-09-08 1997-03-13 Genentech, Inc. Proteine apparentee au vegf
US5916763A (en) * 1995-11-09 1999-06-29 The Regents Of The University Of California Promoter for VEGF receptor
WO1997034920A1 (fr) * 1996-03-21 1997-09-25 Sugen, Inc. Dosages pour inhibiteurs du recepteur tyrosine kinase kdr/flk-1
WO1998039035A1 (fr) * 1997-03-07 1998-09-11 The Wistar Institute Of Anatomy & Biology Procede et compositions permettant de soigner les defauts tissulaires et d'induire l'hypervascularite dans des tissus mammiferes
WO1998055638A1 (fr) * 1997-06-03 1998-12-10 MAX-PLANCK-Gesellschaft zur Förderung der Wissenschaften e.V. Sequences regulatrices capables de commander l'expression d'une sequence d'adn heterologue dans des cellules endotheliales in vivo et leurs utilisations
WO1998058053A1 (fr) * 1997-06-18 1998-12-23 Merck & Co., Inc. Tyrosine kinase receptrice, kdr
WO1999010537A1 (fr) * 1997-08-26 1999-03-04 Board Of Regents, The University Of Texas System Suppresseur de tumeur appele ts10q23.3
WO1999017769A1 (fr) * 1997-10-06 1999-04-15 Basf Aktiengesellschaft Derives d'indeno(1,2-c)-, de naphto(1,2-c)-, et de benzo(6,7)cyclohepta(1,2-c)pyrazole
WO1999021859A1 (fr) * 1997-10-10 1999-05-06 Glaxo Group Limited Azaoxindole, derives et applications
WO1999024440A1 (fr) * 1997-11-11 1999-05-20 Pfizer Products Inc. Derives de thienopyrimidine et thienopyridine utiles comme agents anticancereux
WO2000058511A1 (fr) * 1999-03-26 2000-10-05 Ludwig Institute For Cancer Research Dosage et therapie pour les troubles lymphatiques impliquant la tyrosine kinase flt4 (vegfr-3)

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
M.H.WITTE ET AL.: "PHENOTYPIC AND GENOTYPIC HETEROGENEITY IN FAMILIAL MILROY LYMPHEDEMA", LYMPHOLOGY, vol. 31, no. 4, December 1998 (1998-12-01), pages 145 - 155, XP000990600 *
M.J.KARKKAINEN ET AL.: "Vascular endothelial growth factor receptors in the regulation of angiogenesis and lymphangiogenesis", ONCOGENE, vol. 19, no. 49, 20 November 2000 (2000-11-20), pages 5598 - 5605, XP000990610 *
R.E.FERRELL ET AL.: "Hereditary lymphedema: evidence for linkage and genetic heterogeneity", HUMAN MOLECULAR GENETICS, vol. 7, no. 13, December 1998 (1998-12-01), pages 2073 - 2078, XP000990647 *
T. MÄKINEN ET AL.: "Inhibition of lymphangiogenesis with resulting lymphedema in transgenic mice expressing soluble VEGF receptor-3", NAT.MED., vol. 7, no. 2, February 2001 (2001-02-01), pages 199 - 205, XP000990590 *
V. JOUKOV ET AL.: "A novel vascular endothelial growth factor, VEGF-C, is a ligand for the Flt4 (VEGFR-3) and KDR (VEGFR-2) receptor tyrosine kinases", THE EMBO JOURNAL, vol. 15, no. 2, 1996, pages 290 - 298, XP000100201 *
Y. CAO ET AL.: "Vascular endothelial growth factor C induces angiogenesis in vivo", PROC.NATL.ACAD.SCI. USA, vol. 95, no. 24, 24 November 1998 (1998-11-24), pages 14389 - 14394, XP000994696 *

Also Published As

Publication number Publication date
GB9918057D0 (en) 1999-10-06
WO2001008669A2 (fr) 2001-02-08
AU6302300A (en) 2001-02-19

Similar Documents

Publication Publication Date Title
IL135712A0 (en) Methods for treating hypercoagulable states or acquired protein c deficiency
SE9702860D0 (sv) New use
WO2002058696A3 (fr) Utilisation de composes d'azetidinone substituee pour le traitement de la sitosterolemie
HK1130422A1 (en) A new use of deferiprone
DE69116380T2 (de) Pharmazeutische zubereitung zur behandlung verlängerter gerinnungszeit
WO2001024783A3 (fr) Utilisation de (+)-tramadol, de o-demethyltramadol ou de (+)-o-demethyltramadol, de o-desmethyle-n-mono-desmethyl-tramadol ou de (+)o-desmethyl-n-mono-desmethyl-tramadol pour traiter l'incontinence urinaire
GB0020504D0 (en) Therapeutic method
MY140626A (en) Drug screening methods and method of treatment
WO2001008669A3 (fr) Agents therapeutiques
SE9101840D0 (sv) New medicinal use
PL354961A1 (en) Prevention and treatment of diseases associated with blood coagulation
WO2003001877A3 (fr) Diagnostic et traitement des rejets de tissu cardiaque
IL150541A0 (en) Calcium dicarboxylate ethers, methods of making same, and treatment of vascular disease and diabetes therewith
AU2003283227A8 (en) Method and means for the treatment of vascular and cardiac diseases
NO995459D0 (no) Vevsfaktor for påvirkning av blodkardannelse
WO2001022976A3 (fr) Polytherapie destinee au traitement de l'atherosclerose
BR0316059A (pt) Uso de fosinopril para reduzir eventos cardiovasculares em pacientes de diálise
WO2001058434A3 (fr) Compositions et procedes diagnostiques et therapeutiques destines a agir sur la croissance tumorale, au moyen d'agents mimetiques de l'oxygene
AU2002225994A1 (en) Use of blood coagulation factor xiii for treating haemophilia
Neutel et al. P-373: A comparison of the effects of amlodipine 5 mg/benazepril 20 mg combination therapy to component monotherapy on arterial distensibilitly and left ventricular hypertrophy in patients with mild to moderate hypertension
ATE337783T1 (de) Neue therapeutische verwendung eines derivates von thienylcyclohexylamine zur behandlung von schmerzen
EP1714661A3 (fr) Procedes pour diagnostiquer et traiter des troubles hemostatiques par modulation de l'activité de la p-selectine
RU97111211A (ru) Способ лечения больных с хирургическим эндотоксикозом
Beckles et al. P-375: Attenuation of cardiac hypertrophy in vivo by interference with the jak/Stat pathway
WO2000050023A8 (fr) Methodes visant a reduire la sensibilite d'un muscle lisse vasculaire a endothelium endommage

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

AK Designated states

Kind code of ref document: A3

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: JP